Skip to Content
Merck
All Photos(1)

Documents

Y0001257

Levetiracetam impurity D

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

(2R)-2-(2-Oxopyrrolidin-1-yl)butanamide, (R)-Etiracetam

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C8H14N2O2
CAS Number:
103765-01-1
Molecular Weight:
170.21
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

levetiracetam

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

InChI

1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m1/s1

InChI key

HPHUVLMMVZITSG-ZCFIWIBFSA-N

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Levetiracetam impurity D EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

1359404

Levetiracetam, United States Pharmacopeia (USP) Reference Standard

1359437

Levetiracetam Related Compound B, United States Pharmacopeia (USP) Reference Standard

1359415

Levetiracetam Racemic Mixture, United States Pharmacopeia (USP) Reference Standard

1359426

Levetiracetam Related Compound A, United States Pharmacopeia (USP) Reference Standard

Y0001253

Levetiracetam, European Pharmacopoeia (EP) Reference Standard

Y0001256

Levetiracetam impurity C, European Pharmacopoeia (EP) Reference Standard

Y0001254

Levetiracetam impurity A, European Pharmacopoeia (EP) Reference Standard

Y0000659

Pyrrolidone, European Pharmacopoeia (EP) Reference Standard

PHR1447

Levetiracetam, Pharmaceutical Secondary Standard; Certified Reference Material

Y0001962

Levetiracetam impurity E, European Pharmacopoeia (EP) Reference Standard

Y0001948

Levetiracetam impurity G, European Pharmacopoeia (EP) Reference Standard

PHR2432

Levetiracetam Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2428

Levetiracetam Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2417

Levetiracetam Racemic Mixture, Pharmaceutical Secondary Standard; Certified Reference Material

Pictograms

Exclamation markEnvironment
GHS07,GHS09

Signal Word

Warning

Hazard Statements

H302,H319,H411

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 1

1 of 1

Levetiracetam Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1447

Levetiracetam

[Successful treatment with levetiracetam in a case of Ohtahara syndrome caused by STXBP1 mutation].
S Yamashita et al.
No to hattatsu = Brain and development, 45(1), 64-66 (2013-04-19)
Iu V Popov et al.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 113(5 Pt 2), 48-52 (2013-06-07)
We examined 76 children and adolescents (45 boys (59.2%), 31 girls (40.8%), aged from 6 to 17 years (mean age 14.31 ± 0.3), with the diagnosis of refractory epilepsy using a clinical/psychopathological method and psychometric scales. Marked non-psychotic mental disorders
Helge Bjørnæs et al.
Epilepsy & behavior : E&B, 27(1), 40-48 (2013-02-05)
We performed a double-blind placebo-controlled crossover study of the effects of spike activity during sleep and when awake on learning, long-term memory, vigilance and behavior before and after treatment with levetiracetam in children with electrical status epilepticus during sleep. At
Mika H Martikainen et al.
Epileptic disorders : international epilepsy journal with videotape, 14(4), 438-441 (2012-12-19)
Epilepsy is a common manifestation of mitochondrial disease associated with mutations of the mitochondrial polymerase γ (POLG). Prognosis of mitochondrial epilepsy is often poor and there are few reports of successful treatment of POLG-related epilepsy. We describe a 26-year-old woman
Nitin K Sethi et al.
Drug metabolism and drug interactions, 28(2), 123-124 (2013-02-20)
Levetiracetam is a commonly used broad-spectrum anticonvulsant efficacious in both partial and generalized seizures. It has an extremely favorable side effect profile with few drug-drug interactions, low potential for hematological and hepatic toxicity, and thus has rapidly become the preferred
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service